NCT05732831 2026-04-06Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsTango Therapeutics, Inc.Phase 1/2 Recruiting225 enrolled
NCT03556228 2025-12-11VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaVM Oncology, LLCPhase 1/2 Recruiting242 enrolled